secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2024-02-20T23:59:59+00:00
Accession:  0001193125-24-040034
Event type: leadership
Sentiment:  negative
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Vir Biotechnology CMO Phil Pang to leave at end of March 2024; successor search started
--------------------------------------------------------------------------------

- Executive VP and Chief Medical Officer Phil Pang, M.D., Ph.D. departing at end of March 2024, citing family reasons.
- Company has initiated a search for a new Chief Medical Officer.
- No interim CMO named; transition expected by end of March 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000119312524040034/0001193125-24-040034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000119312524040034/d793408d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-040034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer